Eli Lilly and Co. announced on Thursday that it will file for approval for its next-generation weight loss drug retatrutide in the United States in the first quarter of 2027. The company said the weekly injection treatment delivered "substantial weight loss" in adults with obesity, type 2 diabetes and established cardiovascular disease.
"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health," Lilly Cardiometabolic Health President Kenneth Custer said. Eli Lilly told CNBC that it delayed the approval application process, previously scheduled for this year, as it requires more time to "gather and verify the manufacturing and quality-control data required by regulators."
https://breakingthenews.net/Article/Eli-Lilly-to-seek-obesity-drug-approval-in-Q1-2027/66759980
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.